Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line.
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are.
At the end of each month Chimera Research Group provides you with a monthly summary of ten notable catalysts/events that have been completed during the past month. APRIL 2015: Gilead.
A second busy week of earnings is due out in the space this week. We will see 3 of the 4 remaining large caps report (Gilead, Celgene, Vertex) and a.
Cynapsus is developing a sublingual film formulation of apomorphine for the treatment of acute “Off” episodes in patients with Parkinson’s Disease resulting from long term use of Levodopa. While Levodopa.
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY).
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high.
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas (ADMS) is a company focused on CNS diseases, specifically Parkinson’s (PD) and Alzheimer’s Diseases (AD). It has a low market cap (~$300M), plenty of.
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering.
I know that the sector is doing well and near highs but I cannot shake the feeling that the stocks feel heavy. I do not have a better way to.
Marinus Pharmaceuticals is developing the allopregnanolone analog Ganaxolone as a treatment for epilepsy and other seizure disorders. Its most advanced program is a multinational P3 trial of patients with refractory.
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. February 2015: GILD provided.
San Diego’s Pfenex Inc. is riding the market’s enthusiasm for biosimilars, molecules that although not considered identical, can be automatically substituted for biologic drugs. Previously considered immune to generic competition,.
iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish.
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers.
With this week’s moves in the market and with the JP Morgan Healthcare conference finished, I think its time to bring up the debate again about whether or not biotech.
A quick update on CBSTZ the Cubist CVR. Today Cubist filed an 8-K notifying CVR holders that it intends to purchase all the CVRs at $0.059225 on February 2, 2015..
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie.
This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on.
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.
We are constantly looking for was to improve Chimera and ensure that everyone is getting value for their money. As part of this process, we are looking for feedback from.
Earlier today on twitter there was a robust debate about the weakness seen in GILD and how this is related to fears on the upcoming competition from ABBV/ENTA. It seemed.
GW Pharma’s Tuesday morning R&D meeting looked pretty good. Efficacy data were released for 58 patients with full 12-weeks of epidiolex treatment- 40 of whom have been treated for 16-weeks..
This is the first report on what I want to be a fairly regular set of surveys. I want to keep the surveys short to maximize participation as the more.
The only new data provided by Sarepta were various measures of lung function, including, including %predicted MIP, MEP, and FVC; all of which demonstrated stabilization through 144 weeks for the.
Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.
Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan.
Nice 36-month Natural history study (or “Pane Study”) in Duchenne published essentially confirming what’s pretty much already known- that boys age 7 and over decline more rapidly than those under.
Investors are waiting impatiently for GW Pharma’s December R&D day. The most sought-after information is updates on the Epidiolex Expanded Access Program in Dravet Syndrome. A previous analysis involved 27.